Treatment patterns for schizoaffective disorder and schizophrenia among medicaid patients

Psychiatric Services

Volumn 60, Issue 2, 2009, Pages 210-216

  Olfson, Mark ^a   Marcus, Steven C ^b   Wan, George J ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; DEMOGRAPHY; DEPRESSION; FEMALE; HEALTH CARE NEED; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; MENTAL PATIENT; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 59649100620     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.2.210     Document Type: Article

References (52)

1. Maj M, Pirozzi R, Formicola AM, et al: Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. Journal of Affective Disorders 57:95-98, 2000
2. Faraone SV, Blehar M, Pepple J, et al: Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies. Psychological Medicine 26:401-410, 1996
3. Schwartz JE, Fennig S, Tanenberg-Karant M, et al: Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Archives of General Psychiatry 57:593-600, 2000
4. Adler CM, Strakowski SM: Boundaries of schizophrenia. Psychiatric Clinics of North America 26:1-23, 2003
5. Kempf L, Hussain N, Potash JB: Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders. International Review of Psychiatry 17:9-19, 2005
6. Getz GE, DelBello MP, Fleck DE, et al: Neuroanatomic characterization of schizoaffective disorder using MRI: a pilot study. Schizophrenia Research 55:55-59, 2002
7. Laursen TM, Labouriau R, Licht RW, et al: Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Archives of General Psychiatry 62:841-848, 2005
8. Lake CR, Hurwitz N: Schizoaffective disorders are psychotic mood disorders: there are no schizoaffective disorders. Psychiatry Research 143:255-287, 2006
9. Keck PE Jr, McElroy SL, Strakowski SM, et al: Pharmacologic treatment of schizoaffective disorder. Psychopharmacology 114:529-538, 1994
10. Scully PJ, Owens JM, Kinsella A, et al: Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate. Schizophrenia Research 67:143-155, 2004
11. Widerlöv B, Lindström E, von Knorring L: One-year prevalence of long-term functional psychosis in three different areas of Uppsala. Acta Psychiatrica Scandinavica 96:452-458, 1997
12. Kent S, Fogarty M, Yellowlees P: Heavy utilization of inpatient and outpatient services in a public mental health service. Psychiatric Services 46:1254-1257, 1995
13. Kozak LJ, DeFrances CJ, Hall MJ: National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Statistics 13:1-209, 2006
14. McElroy SL, Keck PE, Strakowski SM: An overview of the treatment of schizoaffective disorder. Journal of Clinical Psychiatry 60(suppl 5):16-22, 1999
15. Flynn J, Grieger TA, Benedek DM: Pharmacologic treatment of hospitalized patients with schizoaffective disorder. Psychiatric Services 53:94-96, 2002
16. Baethge C: Long-term treatment of schizoaffective disorder: review and recommendations. Pharmacopsychiatry 36:45-56, 2003
17. Williams PV, McGlashan TH: Schizoaffective psychosis: I. comparative long-term outcome. Archives of General Psychiatry 44:130-137, 1987
18. Rosenthal NE, Rosenthal LN, Stallone F, et al: Toward the validation of RDC schizoaffective syndromes. International Journal of Clinical Pharmacy Research 5:205-211, 1985
19. Lurie N, Popkin M, Dysken M, et al: Accuracy of diagnoses of schizophrenia in Medicaid claims. Hospital and Community Psychiatry 43:69-71, 1992
20. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630-639, 2002
21. Ward A, Ishak K, Proskoroversusky I, et al: Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clinical Therapeutics 28:1912-1921, 2006
22. Charlson ME, Pomei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373-383, 1987
23. Deyo RA, Cherkin D, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 45:613-619, 1992
24. Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, Va, American Psychiatric Association, 2004. Available at www.guideline.gov/summary/summary.aspx?ss=15&doc-id=5217
25. Levinson DF, Umapathy C, Mushtaq M: Treatment of schizoaffective disorder and schizophrenia with mood symptoms. American Journal of Psychiatry 156:1138-1148, 1999
26. Perlis RH, Welge JA, Bornik LA, et al: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 67:509-516, 2006
27. Bowden CL, Grunze H, Mullen J, et al: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry 66:111-121, 2005
28. Hirschfeld RM, Keck PE Jr, Kramer M, et al: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry 161:1057-1065, 2004
29. Keck PE, Marcus R, Tourkodimitris S, et al: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160:1651-1658, 2003
30. Frank RG, Conti RM, Goldman HH: Mental health policy and psychotropic drugs. Milbank Quarterly 83:271-298, 2005
31. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23:637-651, 1997
32. Weiden PJ, Kozma C, Grogg A, et al: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55:886-891, 2004
33. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692-699, 2004
34. Thompson EE, Neighbors HW, Munday C, et al: Length of stay, referral to aftercare, and rehospitalization among psychiatric inpatients. Psychiatric Services 54:1271-1276, 2003
35. Huxley NA, Rendall M, Sederer L: Psychosocial treatments in schizophrenia: a review of the past 20 years. Journal of Nervous and Mental Disease 188:187-201, 2000
36. Hogarty GE, Flesher S, Ulrich R, et al: Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Archives of General Psychiatry 61:866-876, 2004
37. Andres K, Pfammatter M, Garst F, et al: Effects of a coping-orientated group therapy for schizophrenia and schizoaffective patients: a pilot study. Acta Psychiatrica Scandinavica 101:318-322, 2000
38. Latimer EA, Bush PW, Becker DR, et al: The cost of high-fidelity supported employment programs for people with severe mental illness. Psychiatric Services 55:401-406, 2004
39. Fiander M, Burns T, McHugo GJ, et al: Assertive community treatment across the Atlantic: comparison of model fidelity in the UK and USA. British Journal of Psychiatry 182:248-254, 2003
40. Merikangas KR, Akiskal HS, Angst J, et al: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry 64:543-552, 2007
41. Moreno C, Laje G, Blanco C, et al: National trends in the outpatient treatment of bipolar disorder in youth. Archives of General Psychiatry 64:1032-1039, 2007
42. Kessler RC, McGonagle KA, Swartz M, et al: Sex and depression in the National Comorbidity Survey: I. lifetime prevalence, chronicity and recurrence. Journal of Affective Disorders 29:85-96, 1993
43. Pingitore D, Snowden L, Sansone RA, et al: Persons with depressive symptoms and the treatments they receive: a comparison of primary care physicians and psychiatrists. International Journal of Psychiatry Medicine 31:41-60, 2001
44. Mueser KT, Yarnold PR, Rosenberg SD, et al: Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophrenia Bulletin 26:179-192, 2000
45. Grossman LS, Harrow M, Goldberg JF, et al: Outcome of schizoaffective disorder at two long-term follow-ups: comparisons with outcome of schizophrenia and affective disorders. American Journal of Psychiatry 148:1359-1365, 1991
46. Jäger M, Bottlender R, Strauss A, et al: Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatrica Scandinavica 109:30-37, 2004
47. Tsuang D, Coryell W: An 8-year follow-up of patients with DSM-III-R psychotic depression, schizoaffective disorder, and schizophrenia. American Journal of Psychiatry 150:1182-1188, 1993
48. Sim K, Chan YH, Chong SA, et al: A 24-month prospective outcome study of first-episode schizophrenia and schizoaffective disorder within an early psychosis intervention program. Journal of Clinical Psychiatry 68:1368-1376, 2007
49. Tamblyn R, Laprise R, Hanley JA, et al: Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285:421-429, 2001
50. Law MR, Ross-Degnan D, Soumerai SB: Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric Services 59:540-546, 2008
51. Hermann RC, Rollins CK, Chan JA: Risk-adjusting outcomes of mental health and substance-related care: a review of the literature. Harvard Review of Psychiatry 15:52-69, 2007
52. Zygmunt A, Olfson M, Boyer CA, et al: Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159:1653-1664, 2002